Personalis reports data from AstraZeneca phase 3 clinical trial in lung cancer

Personalis (PSNL) announced new data from an AstraZeneca (AZN) phase 3 clinical trial in lung cancer. The findings demonstrate that Personalis’ highly sensitive molecular residual disease test, NeXT Personal, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer, NSCLC, receiving neoadjuvant therapy. The findings, which will be presented at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain on September 7 (abstract OA02.02), demonstrate that NeXT Personal can be a more sensitive and accurate measure of MRD in the neoadjuvant setting. This supports findings in other cancer types that NeXT Personal can help doctors understand how patients are responding to neoadjuvant therapy, with the potential to guide future treatment decisions.